Dasatinib-induced pleural effusions: A lymphatic network disorder?

American Journal of the Medical Sciences

Volumn 338, Issue 5, 2009, Pages 414-417

  Goldblatt, Mark ^a   Huggins, J Terrill ^a   Doelken, Peter ^a   Gurung, Puncho ^a   Sahn, Steven A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Chylous effusions; Dasatinib; Pleural effusion; Transudates

Indexed keywords

ACICLOVIR; ARSENIC TRIOXIDE; BCR ABL PROTEIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DASATINIB; FOLIC ACID; HYDROXYUREA; IMATINIB; LEVOTHYROXINE; LORAZEPAM; METOPROLOL; NILOTINIB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMEGA 3 FATTY ACID; PENICILLIN G; SUCRALFATE; VALSARTAN;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COMORBIDITY; CYTOPENIA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MALE; PATHOGENESIS; PLEURA EFFUSION; PLEURA FLUID; SKIN BIOPSY; SPLENECTOMY; THORACOCENTESIS; THORAX RADIOGRAPHY; TREATMENT RESPONSE; YELLOW NAIL SYNDROME;

EID: 73649145164     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181ae9227     Document Type: Article

References (18)

1. Savage DG, Antman KH. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 2002;346:683-693
2. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology TM: chronic myelogenous leukemia. Version 2.2010. Available at: www.nccn.org/professionals/physican-gls/PDF/cml.pdf.
3. Silver RT, Talpaz M, Sawyers CL, et al. Four years follow-up of 1027 patients with late chronic phase (CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood 2004;104:11a. Abstract.
4. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS 358425 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65:4500-4505
5. Quintas-Cardama A, Kantarjan H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-3914
6. Morelock SY, Sahn SA. Drug-induced pleural disease. Chest 1999; 116:212-221
7. Huggins JT, Sahn SA. Drug-induced pleural disease. Clin Chest Med 2004;25:141-153
8. Sahn SA. Drug-induced pleural disease. In: Camus P, Rosenow E, editors. Drug-induced iatrogenic lung disease. London: Hodder Arnold; 2009.
9. Antony VB. Drug-induced pleural disease. Clin Chest Med 1998;19: 331-340
10. The drug-induced lung diseases. Available at: www.pneumotox.com.
11. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-3212
12. Bergeron A, Rea D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia a case series. Am J Respir Crit Care Med 2007;176:814-818
13. Staats BA, Ellefson RD, Budahn LL, et al. The lipoprotein profile of chylous and nonchylous pleural effusions. Mayo Clin Proc 1980;55: 700-704
14. Merrigan BA, Winter DC, O'Sullivan GC, et al. Chylothorax. Br J Surg 1997;84:15-20.
15. Sprycel, prescribing information. East Hanover (NJ): Novartis Pharmaceuticals; 2007.
16. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-1312
17. Cao R, Björndahl MA, Religa P, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic vessel metastasis. Cancer Cell 2004;6:333-345
18. Maldonado F, Tazelaar HD, Wang CW, et al. Yellow nail syndrome: Analysis of 41 consecutive patents. Chest 2008;134:375-381